Research 2023-2024
Our research teams, organised across four interrelated themes, are led by 54 Principal Investigators (PIs), driving life-changing innovations and new therapeutic approaches with the aim to maintain and restore vision.
In 2023-2024, we were pleased to have two Early Career Promotions and seven Senior Promotions (including five Moorfields Eye Hospital Honorary staff).
We now have a total of 5 Fellows, and 43 Academic staff, in addition to Early Career Researchers building independence holding their own awards. Also this year, we were pleased to announce that Professor Matteo Carandini, a member of our academic team, has been elected to the Academia Europaea.
In May 2024, we had a large representation of UCL IoO staff and students, including Honorary staff, attending ARVO 2024. The ARVO Annual Meeting was held at Seattle Convention Centre (5-9 May). Many of our staff and students participated with talks and poster presentations. We are very grateful to Zaynab Butt for producing a thorough and enjoyable report on her first experience attending and presenting at this important conference in the world of vision science.
Some research highlights
- October 2023: Effective treatment for rare sight-threatening infection
- February 2024: Blindness from some inherited eye diseases may be caused by gut bacteria
- March 2024: Children with ‘lazy eye’ are at increased risk of serious disease in adulthood
- June 2024: Boosting key protein in eye cells could prevent age-related vision loss
AI model to improve clinical trial recruitment for eye disease
Confocal image from one of our labs on the cover of Journal of Neuroscience
Cell image from one of our labs on the cover of long-standing scientific journal - July 2024: Biomarkers reveal how patients with glaucoma may respond to treatment
- August 2024: First treatment for rare sight-threatening infection approved in Europe
- August 2024: Substitution of a single non-coding nucleotide upstream of TMEM216 causes non-syndromic retinitis pigmentosa and is associated with reduced TMEM216 expression